Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.8.0.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Schedule of Segment Information

Selected financial information for the Company’s operating segments is as follows:

 

    Three Months Ended March 31,  
    2018     2017  
Net revenues – External                
Clinical Laboratory Operations   $ 45,586     $ 684,265  
Hospital Operations     1,556,075       -  
    $ 1,601,661     $ 684,265  
                 
(Loss) income from operations                
Clinical Laboratory Operations   $ (756,083 )   $ (1,292,275 )
Hospital Operations     (1,472,600 )     (467,316 )
Corporate     (1,483,341 )     (1,804,517 )
Eliminations     -       7,851  
    $ (3,712,024 )   $ (3,556,257 )
Depreciation and amortization                
Clinical Laboratory Operations   $ 295,474     $ 434,468  
Hospital Operations     37,728       -  
Corporate     314       312  
Eliminations     -       (7,851 )
    $ 333,515     $ 426,929  
Capital expenditures                
Clinical Laboratory Operations   $ -     $ (100,382 )
Hospital Operations     -       1,090,922  
    $ -     $ 990,540  

 

***` Intersegment revenues are eliminated in consolidation.

 

    March 31, 2018     December 31, 2017  
Total assets                
Clinical Laboratory Operations   $ 1,019,946     $ 1,503,520  
Hospital Operations     2,788,059       2,549,504  
Corporate     3,510,297       3,436,773  
Assets of AMSG and HTS classified as held for sale     243,963       255,566  
Eliminations     (1,424,496 )     (1,454,570 )
    $ 6,137,769     $ 6,290,794